HAL (France)open access
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
Biologic, Infliximab, Value-added medicine, Biosimilar, CT-P13, 0, Innovative biologics, Biobetter
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 330195
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.